Results 81 to 90 of about 4,425,847 (185)

Targeted therapy of DC-CIK cells in renal cell carcinoma [PDF]

, 2023
CIK cells are a heterogeneous population of exceptional T lymphocytes with CD3+CD56+ cells as the primary effectors. CIK cells in combination with DCs have exhibited promising clinical effects on patients with RCC as evidenced by several completed or ...
Zhang, Ying
core  

Disease‐free survival as a surrogate outcome for localized kidney cancer—A systematic review and meta‐analysis

Cancer, Volume 132, Issue 16, 15 August 2026.
Abstract Background Disease‐free survival (DFS) is commonly used as a primary end point in trials for localized renal cell carcinoma (RCC), although its validity as a surrogate for overall survival (OS) remains uncertain. The objective of this study was to evaluate whether DFS is a reliable surrogate end point for OS in this setting.
Constanza Martinez, David Chen, Russell Leong, Nicholas Lum, Karren Xiao, Laith Almasri, Christian K. Kollmannsberger, Srinivas Raman   +7 more
wiley   +1 more source

Extracellular Vesicles in Acute Myeloid Leukemia: Opportunities and Obstacles for Therapeutic Advancement

Journal of Biochemical and Molecular Toxicology, Volume 40, Issue 8, August 2026.
Acute myeloid leukemia (AML) is a disease characterized by uncontrolled proliferation and blocked maturation of hematopoietic stem and progenitor cells. Despite progress in its clinical management, many patients continue to relapse or show limited response to standard therapies, emphasizing the need for novel, safe, and more effective targeted ...
Rongrong Hu, Zaker Ataullev, Luping Lou
wiley   +1 more source

Antibody–Drug Conjugates and Peptide–Drug Conjugates: Current Understandings and Future Perspectives

MedComm, Volume 7, Issue 8, August 2026.
The graphic summarizes the design principles, intracellular trafficking, clinical progress, challenges, and future directions of antibody–drug conjugates (ADCs) and peptide–drug conjugates (PDCs). ADCs consist of a tumor‐targeting antibody, a chemical linker, and a potent payload, whereas PDCs use peptide ligands to deliver cytotoxic, radionuclide, or ...
Ruxi Zheng, Shuiquan Li, Zhigang Zhang, Mengke Niu, Jing Fei, Jiaojiao Zhang, Jianwei Zhou, Kongming Wu, Ming Yi, Tianye Li   +9 more
wiley   +1 more source

Cytokine-induced killer cells: A novel treatment for allergic airway inflammation. [PDF]

PLoS ONE, 2017
The effectiveness of cytokine-induced killer (CIK) cells for treatment of cancers has long been appreciated. Here, we report for the first time that CIK cells can be applied to treat allergic airway inflammation.
Panwadee Pluangnooch, Sunita Timalsena, Adisak Wongkajornsilp, Kitipong Soontrapa   +3 more
doaj   +1 more source

Mechanisms of Therapeutic Resistance and Recent Advances in Glioblastoma Treatment

Immunology &Cell Biology, Volume 104, Issue 7, Page 711-728, August 2026.
Three interconnected processes in glioblastoma (GBM) biology: initiation, stratification, and immunosuppression. 1) Initiation: GBM initiation is proposed to occur through migration of TERT mutation‐bearing neural stem cells from the subventricular zone to the frontal and temporal cortices, where a subsequent oncogenic transformation drives their ...
Emerson Achari, Farah Ahmady‐Nield, Amit Sharma, Ingo G. H. Schmidt‐Wolf, Jarek Maciaczyk, Rodney B. Luwor, Adrian A. Achuthan   +6 more
wiley   +1 more source

Analytic and Dynamic Secretory Profile of Patient-Derived Cytokine-lnduced Killer Cells

Molecular Medicine, 2017
Adoptive immunotherapy with cytokine induced killer (CIK) cells has shown antitumor activity against several kinds of cancer in preclinical models and clinical trials.
Giulia Mesiano, Roberta Zini, Giulia Montagner, Nicoletta Bianchi, Rossella Manfredini, Antonella Chillemi, Massimo Aglietta, Giovanni Grignani, Ilaria Lampronti, Erika Fiorino, Fabio Malavasi, Dario Sangiolo, Roberto Gambari, Davide Ferrari   +13 more
doaj   +1 more source

Cytokine-induced killer (CIK) cell therapy for patients with hepatocellular carcinoma: efficacy and safety [PDF]

, 2012
Purpose To evaluate the efficacy of cytokine-induced killer (CIK) cell therapy in the treatment of hepatocellular carcinoma. Materials and methods Randomized phase II and III trials on CIK cell-based therapy were identified by electronic searches using a
Lei Tang, Hong-Xia Wang, Wang Jian, Wang Hong-Xia, Zhang Zan, Yue Ma, Ma Yue, Jian Wang, Tang Lei, Xu Ying-Chun, Ying-chun Xu, Zan Zhang   +11 more
core   +1 more source

Conductive Additives for Next‐Generation Batteries: Emphasizing the Potential of Bio‐Derived 3D Carbon Architectures at Electrode–Electrolyte Interfaces

Advanced Materials Interfaces, Volume 13, Issue 14, 21 July 2026.
3D conductive frameworks can maintain continuous electron transport, mechanical stability, and interfacial integrity, helping next‐generation batteries operate more efficiently. This Review examines their relevance to Si anodes, all‐solid‐state batteries, and dry‐processed electrodes, and highlights bio‐derived carbons as sustainable, structurally ...
SeoYoung Ha, Inseo Ko, Jongyoung Choi, Weon Ho Shin, Sung Cik Mun, Jong Ho Won   +5 more
wiley   +1 more source

Discovering single cannabidiol or synergistic antitumor effects of cannabidiol and cytokine-induced killer cells on non-small cell lung cancer cells

Frontiers in Immunology
IntroductionA multitude of findings from cell cultures and animal studies are available to support the anti-cancer properties of cannabidiol (CBD). Since CBD acts on multiple molecular targets, its clinical adaptation, especially in combination with ...
Yutao Li, Amit Sharma, Amit Sharma, Michèle J. Hoffmann, Dirk Skowasch, Markus Essler, Hans Weiher, Ingo G. H. Schmidt-Wolf   +7 more
doaj   +1 more source